Hisamitsu America Celebrates 90th Anniversary of Salonpas® with Landmark Sales Achievements

Hisamitsu America announces the 90th anniversary of the introduction of Salonpas®, the top Over-the-Counter (OTC) topical analgesic patch globally. Originating from Japan in 1934, Salonpas® has become a benchmark in the pain relief sector. Hisamitsu Pharmaceutical Co. Inc., the parent company, is recognized for its revolutionary transdermal and topical patch technology worldwide.

The product range has expanded to include various pain relief solutions, such as creams, gels, and liquids. Salonpas® is hailed for its efficacy and innovation, receiving high recommendations from doctors and pharmacists. Furthermore, the Salonpas® Pain Relief Patch was the first FDA-approved OTC topical pain reliever in 2008.

In the U.S. market since 2010, Salonpas® has seen a substantial increase in sales, surpassing $200 million in 2023. Despite this success, market penetration remains a challenge, with less than one-third of U.S. households purchasing products within the External Analgesics category. Hisamitsu America aims to broaden its user base, emphasizing non-pill-based pain relief options.

Online engagement has also seen remarkable growth, with Salonpas® showing a near double increase in search terms in 2023. It boasts the largest Facebook fan base among OTC analgesic brands. The recent introduction of the Salonpas Lidocaine 4% Pain Relieving FLEX Patch has been well-received, becoming the top new product in its category.

As Hisamitsu America commemorates this milestone, it reaffirms its dedication to advancing pain relief solutions. Its continuous innovation and commitment to quality aim to enhance the quality of life globally.